CORONA Remedies receives EU-GMP certification for hormone facility
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
The Ma’anshan site approval covers pastilles, oral liquids, and powders
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product
Subscribe To Our Newsletter & Stay Updated